Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PRAN's Cash to Debt is ranked higher than
94% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. PRAN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PRAN' s Cash to Debt Range Over the Past 10 Years
Min: 16.62  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.94
PRAN's Equity to Asset is ranked higher than
89% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. PRAN: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
PRAN' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.82 Max: 0.97
Current: 0.94
0.57
0.97
Interest Coverage No Debt
PRAN's Interest Coverage is ranked higher than
92% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PRAN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PRAN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 6.66
M-Score: -2.38
WACC vs ROIC
3.97%
-164.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -159.84
PRAN's Operating margin (%) is ranked lower than
59% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. PRAN: -159.84 )
Ranked among companies with meaningful Operating margin (%) only.
PRAN' s Operating margin (%) Range Over the Past 10 Years
Min: -3850.92  Med: -1717.11 Max: -152.91
Current: -159.84
-3850.92
-152.91
Net-margin (%) -115.56
PRAN's Net-margin (%) is ranked lower than
56% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. PRAN: -115.56 )
Ranked among companies with meaningful Net-margin (%) only.
PRAN' s Net-margin (%) Range Over the Past 10 Years
Min: -3945.4  Med: -1648.28 Max: -90.62
Current: -115.56
-3945.4
-90.62
ROE (%) -20.08
PRAN's ROE (%) is ranked higher than
59% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. PRAN: -20.08 )
Ranked among companies with meaningful ROE (%) only.
PRAN' s ROE (%) Range Over the Past 10 Years
Min: -175.62  Med: -95.81 Max: -15.33
Current: -20.08
-175.62
-15.33
ROA (%) -18.68
PRAN's ROA (%) is ranked higher than
58% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. PRAN: -18.68 )
Ranked among companies with meaningful ROA (%) only.
PRAN' s ROA (%) Range Over the Past 10 Years
Min: -139.97  Med: -76.61 Max: -14.1
Current: -18.68
-139.97
-14.1
ROC (Joel Greenblatt) (%) -88.93
PRAN's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. PRAN: -88.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRAN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -21767.52  Med: -8028.58 Max: -154.1
Current: -88.93
-21767.52
-154.1
Revenue Growth (3Y)(%) 13.00
PRAN's Revenue Growth (3Y)(%) is ranked higher than
66% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. PRAN: 13.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRAN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -30.70 Max: 166.8
Current: 13
0
166.8
EBITDA Growth (3Y)(%) -12.60
PRAN's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. PRAN: -12.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRAN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -22.50 Max: 25.1
Current: -12.6
0
25.1
EPS Growth (3Y)(%) -12.60
PRAN's EPS Growth (3Y)(%) is ranked lower than
59% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. PRAN: -12.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRAN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -12.60 Max: 71
Current: -12.6
0
71
» PRAN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with PRAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CNAT, ROCO:4169, XKRX:036480, XPAR:ALQGC, ASX:MDC, OTCPK:EMIS » details
Traded in other countries:PBT.Australia, PBNN.Germany, PRNAF.USA,
Prana Biotechnology Ltd is engaged in the development of therapeutic drugs designed to treat the causes of degeneration of the brain as the aging process progresses including Alzheimer's disease, Huntington's disease and Parkinson's disease.

Prana Biotechnology Ltd was incorporated on November 11, 1997. The Company is a development stage company at an early stage in the development of its pharmaceutical products. The Company's activities include research into Alzheimer 's disease and other age-related degenerative disorders. Its compound PBT2, is manufactured by Dr. Reddys based in Hyderabad, India. It competes with pharmaceutical companies, biotechnoloy firms, universities and research institutions. The Company is subject to governmental laws and regulations.

Ratios

vs
industry
vs
history
P/B 1.18
PRAN's P/B is ranked higher than
88% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. PRAN: 1.18 )
Ranked among companies with meaningful P/B only.
PRAN' s P/B Range Over the Past 10 Years
Min: 0.82  Med: 6.51 Max: 34.32
Current: 1.18
0.82
34.32
P/S 6.15
PRAN's P/S is ranked higher than
68% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. PRAN: 6.15 )
Ranked among companies with meaningful P/S only.
PRAN' s P/S Range Over the Past 10 Years
Min: 4.62  Med: 63.33 Max: 260
Current: 6.15
4.62
260
EV-to-EBIT -2.59
PRAN's EV-to-EBIT is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. PRAN: -2.59 )
Ranked among companies with meaningful EV-to-EBIT only.
PRAN' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.7  Med: -4.60 Max: 0.8
Current: -2.59
-53.7
0.8
EV-to-EBITDA -2.61
PRAN's EV-to-EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. PRAN: -2.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -53.9  Med: -4.60 Max: 0.8
Current: -2.61
-53.9
0.8
Current Ratio 16.39
PRAN's Current Ratio is ranked higher than
87% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. PRAN: 16.39 )
Ranked among companies with meaningful Current Ratio only.
PRAN' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 5.55 Max: 18.98
Current: 16.39
1.35
18.98
Quick Ratio 16.39
PRAN's Quick Ratio is ranked higher than
87% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. PRAN: 16.39 )
Ranked among companies with meaningful Quick Ratio only.
PRAN' s Quick Ratio Range Over the Past 10 Years
Min: 1.35  Med: 5.55 Max: 18.98
Current: 16.39
1.35
18.98
Days Sales Outstanding 521.05
PRAN's Days Sales Outstanding is ranked lower than
97% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. PRAN: 521.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.85  Med: 70.08 Max: 366.29
Current: 521.05
0.85
366.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.60
PRAN's Price/Net Cash is ranked higher than
90% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. PRAN: 1.60 )
Ranked among companies with meaningful Price/Net Cash only.
PRAN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.07  Med: 8.00 Max: 149
Current: 1.6
1.07
149
Price/Net Current Asset Value 1.14
PRAN's Price/Net Current Asset Value is ranked higher than
94% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. PRAN: 1.14 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PRAN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 7.25 Max: 149
Current: 1.14
1.07
149
Price/Tangible Book 1.18
PRAN's Price/Tangible Book is ranked higher than
91% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. PRAN: 1.18 )
Ranked among companies with meaningful Price/Tangible Book only.
PRAN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.64  Med: 7.25 Max: 149
Current: 1.18
0.64
149
Earnings Yield (Greenblatt) (%) -38.60
PRAN's Earnings Yield (Greenblatt) (%) is ranked lower than
81% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. PRAN: -38.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRAN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 124  Med: 6283.30 Max: 6283.3
Current: -38.6
124
6283.3

More Statistics

Revenue (TTM) (Mil) $5.00
EPS (TTM) $ -0.65
Beta0.27
Short Percentage of Float0.46%
52-Week Range $2.70 - 9.72
Shares Outstanding (Mil)8.90

Analyst Estimate

Jun16 Jun17
Revenue (Mil $)
EPS ($) -0.03 -0.03
EPS without NRI ($) -0.03 -0.03
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for PRAN

Headlines

Articles On GuruFocus.com

More From Other Websites
Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA... Apr 11 2016
Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA... Apr 11 2016
Prana Biotechnology Half Year Investor Report Feb 26 2016
Prana Biotechnology Half Year Investor Report Feb 26 2016
PRANA BIOTECHNOLOGY LTD Financials Dec 08 2015
Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award Nov 16 2015
Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award Nov 16 2015
AGM Presentation Nov 12 2015
Prana AGM Webcast Details Nov 09 2015
Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement Nov 09 2015
Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement Nov 09 2015
Preliminary Final Report (Appendix 4E) Aug 27 2015
Prana Reports FY15 Financial Results Aug 27 2015
Prana Reports FY15 Financial Results Aug 27 2015
Prana reports FY15 financial results Aug 26 2015
Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial Jun 30 2015
Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial Jun 30 2015
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease Jun 01 2015
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease Jun 01 2015
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease Jun 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)